CN115381876A - Oral preparation for relaxing heart and reducing fat and preparation method thereof - Google Patents
Oral preparation for relaxing heart and reducing fat and preparation method thereof Download PDFInfo
- Publication number
- CN115381876A CN115381876A CN202211103084.2A CN202211103084A CN115381876A CN 115381876 A CN115381876 A CN 115381876A CN 202211103084 A CN202211103084 A CN 202211103084A CN 115381876 A CN115381876 A CN 115381876A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart
- soothing
- lipid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 210000002216 heart Anatomy 0.000 title claims abstract description 21
- 230000002040 relaxant effect Effects 0.000 title claims abstract description 5
- 239000008280 blood Substances 0.000 claims abstract description 29
- 210000004369 blood Anatomy 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 16
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 16
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 12
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 10
- 241001013934 Erigeron breviscapus Species 0.000 claims abstract description 9
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 9
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 9
- 241000913745 Spatholobus Species 0.000 claims abstract description 9
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 8
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 8
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 8
- 244000138993 panchioli Species 0.000 claims abstract description 7
- 239000002023 wood Substances 0.000 claims abstract description 7
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 2
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 23
- 238000005303 weighing Methods 0.000 claims description 21
- 150000002632 lipids Chemical class 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 239000006188 syrup Substances 0.000 claims description 14
- 235000020357 syrup Nutrition 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 230000008961 swelling Effects 0.000 claims description 10
- 239000000679 carrageenan Substances 0.000 claims description 7
- 235000010418 carrageenan Nutrition 0.000 claims description 7
- 229920001525 carrageenan Polymers 0.000 claims description 7
- 229940113118 carrageenan Drugs 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 3
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 3
- 229920002581 Glucomannan Polymers 0.000 claims description 3
- 239000004378 Glycyrrhizin Substances 0.000 claims description 3
- 229920002752 Konjac Polymers 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 229940046240 glucomannan Drugs 0.000 claims description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 3
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 239000000252 konjac Substances 0.000 claims description 3
- 235000010485 konjac Nutrition 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 229930189775 mogroside Natural products 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 239000001828 Gelatine Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 230000001737 promoting effect Effects 0.000 abstract description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 206010020772 Hypertension Diseases 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 206010033557 Palpitations Diseases 0.000 abstract description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 206010022437 insomnia Diseases 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 10
- 241000180649 Panax notoginseng Species 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 241001092040 Crataegus Species 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 241001106477 Paeoniaceae Species 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010039986 Senile pruritus Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940041672 oral gel Drugs 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- -1 puerarin-7-xyloside Chemical compound 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 2
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 2
- ZWSNUPOSLDAWJS-QNDFHXLGSA-N 6,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound OC[C@H]1O[C@@H](Oc2ccc(cc2)-c2coc3cc(O)c(O)cc3c2=O)[C@H](O)[C@@H](O)[C@@H]1O ZWSNUPOSLDAWJS-QNDFHXLGSA-N 0.000 description 1
- VWEWSCDQMVNOJP-IPOZFMEPSA-N 7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=CC=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)C=C1 VWEWSCDQMVNOJP-IPOZFMEPSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 244000185386 Thladiantha grosvenorii Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000009427 jiangzhi Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an oral preparation for relaxing heart and reducing fat and a preparation method thereof, belonging to the field of food processing and comprising the following raw materials in parts by weight: 60-80 parts of salvia miltiorrhiza bunge, 10-18 parts of giant knotweed, 11000-15000 parts of pseudo-ginseng, 5-10 parts of dalbergia wood, 10000-14000 parts of kudzu root, 2-8 parts of peach kernel, 10-15 parts of red paeony root, 50-90 parts of hawthorn, 10-17 parts of safflower, 10-18 parts of suberect spatholobus stem and 10-18 parts of erigeron breviscapus; the invention also discloses a preparation method of the oral preparation; the oral preparation prepared by the invention is elastic and delicious, has low sugar content, is easy to chew and digest, has the effects of promoting blood circulation to remove blood stasis, activating yang to reduce turbidity, promoting qi circulation to relieve pain, improving palpitation and insomnia, reducing blood fat and the like, and is particularly suitable for people with hypertension and hyperlipidemia and the like.
Description
Technical Field
The invention belongs to the field of food processing, and particularly relates to an oral preparation for soothing heart and reducing blood fat and a preparation method thereof.
Background
Hyperlipidemia (hyperlipidemia), often referred to as hyperlipidemia, is also medically known as dyslipidemia (dyslipemia), and generally refers to an increase in plasma Triglycerides (TG) and/or Total Cholesterol (TC), and also includes an increase in low density lipoprotein cholesterol (LDL-C) and a decrease in high density lipoprotein cholesterol (HDL-C). Lipid intake is excessive, and abnormal lipoprotein synthesis and metabolic processes can lead to abnormal blood lipids. These abnormally elevated lipids are deposited in cells and on the walls of blood vessels through certain mechanisms to form atherosclerotic plaques, which cause stenosis and even occlusion of the blood vessel lumen, resulting in severe consequences such as limb ischemia, coronary heart disease, cerebral apoplexy, and the like. Long-term hyperlipidemia can lead to the appearance of a series of concomitant diseases: 1. symptoms such as chest distress, chest pain, dizziness, claudication and the like can occur when atherosclerosis is caused; 2. polydipsia and polyuria symptoms may occur when diabetes is caused; 3. excessive lipid is deposited in the liver and spleen, and the volume of the liver and spleen is increased in patients.
The traditional Chinese medicine holds that the occurrence of the hyperlipidemia phenomenon is mainly related to the formation of turbid phlegm and blocking of channels, or the failure of blood stasis and the obstruction of channels, and the formation and development of turbid phlegm and blood stasis are closely related to the dysfunction of the viscera such as spleen, kidney, liver, heart and the like. The traditional Chinese medicine adopts treatment based on syndrome differentiation, and adopts corresponding prescription to decoct traditional Chinese medicine for treating hyperlipidemia. However, the traditional Chinese medicine boiled by the traditional Chinese medicine can not meet the life rhythm of modern people, so that the functional health food is more and more popular. Gel foods are increasingly popular among consumers due to their low calorie, easy digestion, elastic mouthfeel, and easy chewing characteristics. The existing gel food mainly adopts pure candies, and cannot meet the requirements of people on heart soothing and lipid lowering, so that the health-care edible gel prepared by adding medicinal and edible plants or medicinal materials is required to meet the requirements of people on heart soothing and lipid lowering.
Disclosure of Invention
In order to overcome the problems in the background art, the invention aims to provide the heart-soothing and lipid-lowering oral preparation, which is prepared by decocting a plurality of medicinal materials into a medicament, dispersing the effective ingredients of the medicament into gel, and fully coating the effective ingredients of the medicinal materials by the gel, thereby increasing the retention time of the medicament in a user body, ensuring the complete absorption of the medicament and being convenient and quick to take.
The invention also aims to provide a preparation method of the oral preparation.
In order to realize the purpose, the invention is realized by the following technical scheme:
the oral preparation for soothing heart and reducing blood fat comprises the following raw materials in parts by weight: 60-80 parts of salvia miltiorrhiza bunge, 10-18 parts of giant knotweed, 11000-15000 parts of pseudo-ginseng, 5-10 parts of dalbergia wood, 10000-14000 parts of kudzu root, 2-8 parts of peach kernel, 10-15 parts of red paeony root, 50-90 parts of hawthorn, 10-17 parts of safflower, 10-18 parts of suberect spatholobus stem and 10-18 parts of erigeron breviscapus.
Further, the heart-soothing and lipid-lowering oral preparation also comprises the following raw materials in parts by weight: 10-60 parts of rubber powder, 1.5-450 parts of sweetener and 0.3-0.6 part of preservative.
Furthermore, the rubber powder is one or the combination of any more of carrageenan, konjac glucomannan and gelatin.
Furthermore, the sweetening agent is one or the combination of any several of sucrose, xylitol, sucralose, glycyrrhizin and mogroside.
Furthermore, the preservative is one or the combination of any several of sorbic acid, potassium sorbate and sodium benzoate.
The preparation method of the oral preparation for soothing heart and reducing blood fat comprises the following steps: (1) Weighing the raw materials according to the parts by weight, decocting with water for 3 times, each time for 1.5 hours, filtering the decoction, combining the filtrates, and concentrating to obtain an extract with a relative density of 1.2 for later use;
(2) Weighing the rubber powder according to the weight parts, adding water to soak and dissolve, and obtaining a colloidal solution for later use after swelling or complete dissolution;
(3) Weighing a sweetening agent and a preservative according to the weight parts, adding water to dissolve, and heating to obtain syrup for later use;
(4) And (3) mixing the extractum, the colloidal solution and the syrup prepared in the steps (1), (2) and (3), adding water to reach the total weight of 1500 parts, uniformly mixing, filtering, sterilizing and subpackaging to obtain the traditional Chinese medicine.
Pueraria lobata (Willd.) Ohwi is dried root of Pueraria lobata Ohwi of Leguminosae, and is called as Pueraria lobata Ohwi. Mainly contains hydrate, vegetable protein, a plurality of vitamins and mineral substances, and also contains flavonoid substances: daidzein and daidzin can be daidzein-4,7-diglucoside, puerarin-7-xyloside, puerarin, radix Puerariae vine and isoflavone glycoside, etc. Kudzuvine root has the functions of expelling pathogenic factors from muscles, allaying fever, promoting eruption, promoting the production of body fluid to quench thirst, invigorating yang and stopping diarrhea. It is commonly used to characterize fever, measles without adequate eruption, thirst due to febrile disease, diabetes due to yin deficiency, dysentery due to heat-purging, diarrhea due to spleen deficiency, etc. Has the effects of improving hepatocyte regeneration ability, recovering normal liver skill, promoting bile secretion, and preventing fat accumulation in liver. Promoting metabolism, enhancing liver detoxification function, and preventing alcohol damage to liver. Radix Puerariae can also be used for preventing and treating cardiovascular and cerebrovascular diseases such as coronary atherosclerotic heart disease, angina pectoris, myocardial infarction, and cerebral arteriosclerosis by improving myocardial ischemia state. By strengthening the autoimmune function of the hepatobiliary cells, the virus invasion is resisted.
Giant knotweed rhizome is distributed in northwest, east, middle, south and southwest areas. Has effects of promoting diuresis, eliminating jaundice, clearing heat, removing toxic substance, removing blood stasis, relieving pain, relieving cough, and eliminating phlegm. Can be used for treating jaundice due to damp-heat pathogen, stranguria with turbid discharge, leukorrhagia, rheumatalgia, carbuncle, swelling, sore, scald due to water and fire, amenorrhea, abdominal mass, contusion injury, and cough due to lung heat.
Erigeron breviscapus, pungent and slightly bitter in flavor, warm in nature and entering heart and liver meridians. It has the functions of promoting blood circulation to disperse meridian obstruction, relieving pain, expelling wind and cold. It is commonly used for apoplexy, hemiplegia, thoracic obstruction, cardialgia, rheumatic arthralgia, headache, toothache, etc.
The hawthorn has the functions of reducing blood fat, blood pressure, strengthening heart, resisting arrhythmia and the like, is also a good medicine for strengthening spleen, stimulating appetite, promoting digestion, removing stagnation, promoting blood circulation and reducing phlegm, and has good curative effects on symptoms such as chest, diaphragm, spleen fullness, hernia, blood stasis, amenorrhea and the like. The vitexin is a flavonoid compound in hawthorn, is a drug with strong anticancer effect, and the extract of the vitexin has certain effects on inhibiting the growth, proliferation and infiltration and metastasis of cancer cells in vivo.
Radix Paeoniae Rubra is used for treating heat entering nutrient-blood, warm toxin and macula, hematemesis and epistaxis, conjunctival congestion and swelling and pain, liver depression and hypochondriac pain, amenorrhea and dysmenorrhea, addiction and abdominal pain, traumatic injury, carbuncle, swelling and sore and ulcer.
One of the main sources of spatholobus stem has the efficacies of dispelling wind and activating blood circulation, relaxing tendons and activating collaterals. It can be used for treating soreness of waist and knees, numbness, paralysis, and menoxenia.
The invention has the beneficial effects that:
(1) Compared with the gel candy added with concentrated juice on the market, the oral gel has the effects of improving the immunity of medicinal materials and preventing cardiovascular diseases, and is particularly suitable for middle-aged and elderly people with low immunity and cardiovascular diseases needing health care and prevention. Is also suitable for people with hypertension, hyperlipidemia, etc.
(2) Compared with the tablet for eliminating dampness or the health-care product tablet on the market, the oral gel prepared by the invention is elastic and delicious, has low sugar content, is easy to chew and digest, has the effects of promoting blood circulation to remove blood stasis, activating yang to reduce turbidity, promoting qi circulation to relieve pain, improving palpitation and insomnia, reducing blood fat and the like, and is particularly suitable for people with hypertension and hyperlipidemia and the like.
(3) Because tanshinone has certain functions in the aspects of expanding blood vessels, protecting endothelial cells, resisting oxidation, anticoagulation, fibrosis, arrhythmia and the like, tanshinone has obvious side effects as a medicament for activating blood and dissolving stasis, and is most commonly seen in bleeding, such as gingival bleeding or gastrointestinal bleeding, hematuria, purpura occurring under the skin, cough and hemoptysis and other symptoms; if the female uses the medicine frequently or irregularly, the side effects such as excessive menstruation or irregular menstruation can be caused; 3. most of the blood-activating and stasis-resolving herbs are warm in nature and flavor, and are easy to consume yin and fluid in the body to cause dry mouth and thirst or dry eyes and other uncomfortable symptoms of essence and blood deficiency, and the serious symptoms can cause coma and vertigo.
The invention combines the pseudo-ginseng, and pharmacological research shows that the pseudo-ginseng extract not only has good bidirectional pharmacological effects of stopping bleeding, promoting blood circulation to remove blood stasis, but also has obvious blood enriching effect, can promote the division and growth of various blood cells such as red blood cells, white blood cells, blood platelets and the like in blood, increase the number of the blood cells, and keep the normal level. The notoginseng contains notoginseng essence, which is a naturally-occurring non-protein amino acid, can obviously shorten the blood coagulation time, the prothrombin time and the thrombin time, the hemostatic effect of the notoginseng essence is caused by promoting the vasoconstriction of histamine, and the notoginseng essence can achieve the effect of enhancing the hemostasis by comprehensively influencing a blood coagulation system, a platelet aggregation system and a fibrinolysis system, namely activating various endogenous blood coagulation factors, improving the fiber in plasma to promote the aggregation of a first phase and a second phase of platelets, inhibiting the content of the fibrinogen, and preventing fibrinolysis and forming thrombus. In the compatibility of the invention, the medicine contains partial effective components for promoting blood circulation and removing blood stasis, and partial bleeding side effects can be generated, so the compatibility of the invention adopts pseudo-ginseng, the dencichine in the pseudo-ginseng and the components for promoting blood circulation and removing blood stasis in the compatibility of the invention have synergistic effect, the occurrence of side effects is reduced, and the effects of relieving heart and reducing blood fat of the medicine are better exerted.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, preferred embodiments of the present invention will be described in detail below to facilitate understanding of the skilled person.
Example 1
Weighing the following raw materials in parts by weight: 60 parts of salvia miltiorrhiza bunge, 18 parts of giant knotweed, 14350 parts of pseudo-ginseng, 10 parts of dalbergia wood, 10000 parts of kudzuvine root, 5.6 parts of peach kernel, 14.6 parts of red paeony root, 90 parts of hawthorn, 13.6 parts of safflower, 18 parts of suberect spatholobus stem and 10 parts of erigeron breviscapus, the raw materials are decocted for 3 times by water, 1.5 hours for each time, decoction liquid is filtered, filtrate is combined, and the mixture is concentrated into extract with the relative density of 1.2 for later use;
(2) Weighing 60 parts of gelatin, adding water to soak and dissolve the gelatin, and obtaining a colloidal solution for later use after swelling or complete dissolution;
(3) Weighing 450g of xylitol and 0.3g of potassium sorbate, adding water for dissolving, and heating to obtain syrup for later use;
(4) And (3) mixing the extractum, the colloidal solution and the syrup prepared in the steps (1), (2) and (3), adding water to reach the total weight of 1500 parts, uniformly mixing, filtering, sterilizing and subpackaging to obtain the traditional Chinese medicine.
Example 2
Weighing the following raw materials in parts by weight: 80 parts of salvia miltiorrhiza bunge, 12 parts of giant knotweed, 15000 parts of pseudo-ginseng, 5 parts of rosewood, 11230 parts of kudzuvine root, 7.1 parts of peach seed, 15 parts of red paeony root, 68.2 parts of hawthorn, 11.2 parts of safflower, 10 parts of suberect spatholobus stem and 11.6 parts of erigeron breviscapus, decocting the raw materials with water for 3 times, 1.5 hours each time, filtering decoction, combining filtrates, concentrating into an extract with the relative density of 1.2 for later use;
(2) Weighing 10 parts of carrageenan, adding water to soak and dissolve the carrageenan, and obtaining a colloidal solution for later use after swelling or complete dissolution;
(3) Weighing 350 parts of xylitol and 0.3 part of sodium benzoate, adding water to dissolve, and heating to obtain syrup for later use;
(4) And (3) mixing the extractum, the colloidal solution and the syrup prepared in the steps (1), (2) and (3), adding water to reach the total weight of 1500 parts, uniformly mixing, filtering, sterilizing and subpackaging to obtain the traditional Chinese medicine.
Example 3
Weighing the following raw materials in parts by weight: 73.2 parts of salvia miltiorrhiza bunge, 13.72 parts of giant knotweed, 13720 parts of pseudo-ginseng, 6.8 parts of dalbergia wood, 13720 parts of kudzuvine root, 4.56 parts of peach kernel, 13.72 parts of red paeony root, 68.56 parts of hawthorn, 13.72 parts of safflower, 13.72 parts of suberect spatholobus stem and 13.72 parts of erigeron breviscapus, decocting the raw materials with water for 3 times, 1.5 hours each time, filtering the decoction, combining the filtrates, and concentrating into an extract with the relative density of 1.2 for later use;
(2) Weighing 50 parts of konjac glucomannan, adding water to soak and dissolve, and obtaining a colloidal solution for later use after swelling or complete dissolution;
(3) Weighing 350 parts of sucrose, 1.5 parts of momordica grosvenori sweet and 0.6 part of sorbic acid, adding water for dissolving, and heating to obtain syrup for later use;
(4) And (3) mixing the extractum, the colloidal solution and the syrup prepared in the steps (1), (2) and (3), adding water to reach the total weight of 1500 parts, uniformly mixing, filtering, sterilizing and subpackaging to obtain the traditional Chinese medicine.
Example 4
Weighing the following raw materials in parts by weight: 72 parts of salvia miltiorrhiza bunge, 10 parts of giant knotweed, 11000 parts of pseudo-ginseng, 7.2 parts of dalbergia wood, 14000 parts of kudzuvine root, 8 parts of peach kernel, 10 parts of red paeony root, 70.6 parts of hawthorn, 17 parts of safflower, 17 parts of suberect spatholobus stem and 15.9 parts of erigeron breviscapus, the raw materials are decocted for 3 times by water, 1.5 hours for each time, decoction liquid is filtered, filtrate is combined, and the mixture is concentrated into extract with the relative density of 1.2 for standby;
(2) Weighing 15 parts of carrageenan, adding water to soak and dissolve the carrageenan, and obtaining a colloidal solution for later use after swelling or complete dissolution;
(3) Weighing 400 parts of xylitol, 3 parts of glycyrrhizin and 0.5 part of potassium sorbate, adding water to dissolve, and heating to obtain syrup for later use;
(4) And (3) mixing the extractum, the colloidal solution and the syrup prepared in the steps (1), (2) and (3), adding water to reach the total weight of 1500 parts, uniformly mixing, filtering, sterilizing and subpackaging to obtain the traditional Chinese medicine.
Example 5
Weighing the following raw materials in parts by weight: 68 parts of salvia miltiorrhiza bunge, 15.5 parts of giant knotweed, 12800 parts of pseudo-ginseng, 5 parts of dalbergia wood, 12500 parts of kudzuvine root, 2 parts of peach kernel, 12.3 parts of red paeony root, 50 parts of hawthorn, 15.6 parts of safflower, 14.9 parts of suberect spatholobus stem and 18 parts of erigeron breviscapus, the raw materials are decocted by water for 3 times, 1.5 hours each time, the decoction is filtered, the filtrate is combined, and the mixture is concentrated into extract with the relative density of 1.2 for standby;
(2) Weighing 20 parts of carrageenan and 20 parts of gelatin, adding water, soaking and dissolving, and obtaining a colloidal solution for later use after swelling or complete dissolution;
(3) Weighing 300 parts of xylitol, 1.5 parts of sucralose and 0.6 part of potassium sorbate, adding water for dissolving, and heating to obtain syrup for later use;
(4) And (3) mixing the extractum, the colloidal solution and the syrup prepared in the steps (1), (2) and (3), adding water to reach the total weight of 1500 parts, uniformly mixing, filtering, sterilizing and subpackaging to obtain the traditional Chinese medicine.
The product advantages of the present invention were verified by the following tests.
The oral formulations of the invention (examples 2 or 3) were compared to the comparative examples: the heart-soothing and lipid-lowering tablets were compared. The comparative example, shuxin Jiangzhi tablet, is prepared according to the national drug standard WS 3-B-2799-97.
The effect is compared as follows:
60 people with hypertension were recruited and divided into two groups, aged 40-60 years, half of both sexes. The two groups took the heart-soothing and lipid-lowering tablets (3 times a day, 4 tablets at a time) and the oral preparation of the present invention (example 3) (3 times a day, 2 bags at a time), respectively. After one month of administration, the oral preparation (example 3) was superior to the heart-soothing and lipid-lowering tablet in the improvement of symptoms in all aspects. The comments were collected as follows:
test one: 60 patients with hypertension were taken as study subjects, the patients were divided into A, B groups, each group had 30 patients, group A was treated with heart soothing and lipid lowering tablets, group B was treated with oral preparation (example 3), and the change of blood pressure and blood lipid after treatment was observed in the two groups of patients, and clinical effects were observed.
As a result: the total effective rate after treatment in group B is 82.5%, which is higher than 72.0% in group A, and the difference is statistically significant (P < 0.05).
The diastolic pressure and the systolic pressure of group B were (78.26. + -. 4.41) mm Hg and (129.58. + -. 6.25) mm Hg, respectively, and were lower than those of group A (the diastolic pressure and the systolic pressure were (80.02. + -. 3.61) mm Hg and (130.58. + -. 4.25) mm Hg, respectively).
The blood lipid indexes TG, TC and LDL-C in the group B are respectively (2.21 +/-0.48) mmol/L, (2.38 +/-0.71) mmol/L and (2.01 +/-0.69) mmol/L which are lower than those in the group A (the blood lipid indexes TG, TC and LDL-C in the group A are respectively (3.11 +/-0.56) mmol/L, (3.88 +/-0.79) mmol/L and (3.19 +/-0.87) mmol/L), and the difference has statistical significance (P is less than 0.05).
The HDL-C in group B is (1.79 + -0.44) mmol/L, which is higher than that in group A (1.14 + -0.12) mmol/L), and the difference is statistically significant (P < 0.05). And (4) conclusion: the oral preparation (example 3) is used for treatment, so that the blood pressure and the blood fat of the hypertension patient can be controlled at normal level, and the clinical treatment effect is improved.
And (2) test II: 30 people were recruited, aged 19-60 years, male and female halves. Each person took the heart-soothing and lipid-lowering tablets in the first week and the oral preparation in the second week (example 2), and the opinions were collected: the oral formulation (example 2) is believed to have a taste superior to 25 people with the heart soothing and lipid lowering tablets. The ease of use of the oral gel (example 2) was superior to that of the heart soothing lipid lowering tablets by 20.
And (3) testing three: 200 people are gathered, aged 65-80 years, half of all people are divided into 8 groups, and observation for treating senile pruritus cutanea is carried out. For treating group A1, SHUXINJIANGZHI tablet is prepared by directly grinding SHUXINJIANGZHI tablet into powder, concocting with water to obtain paste, and applying to affected part for 3 times a day, 4 tablets once. Group A2, SHUXINJIANGZHI tablet, is administered orally with warm water 3 times daily, 4 tablets each time. Group B1 oral formulations (example 2) treatment, example 2 was applied directly to the affected area. Group B2 oral formulations (example 2) were treated orally, directly, 3 times a day, 1 strip at a time. Group C1 Notoginseng radix tablet (prepared by pulverizing Notoginseng radix 500g into fine powder, adding adjuvant, granulating, and pressing into 1000 tablets) is prepared by directly grinding Notoginseng radix tablet into powder, concocting with water into paste, applying to affected part, 3 times a day, and 6 tablets once. The Notoginseng radix tablet for C2 group is administered with warm water 3 times daily, 6 tablets each time. Group D1 Yimaikang tablets (prepared by mixing herba Erigerontis extract 160g with starch 150g, drying below 75 deg.C, pulverizing, adding dextrin, granulating with 60% ethanol, pressing into 1000 tablets, and coating with sugar coating) for treatment, directly grinding Yimaikang tablets into powder, concocting with water into paste, and applying to affected part for 3 times a day, 2 tablets at a time. The group D2 Yimaikang tablets are taken with warm water 3 times a day and 2 tablets at a time. Each group was treated for 1 month. The results are given in table 1 below.
TABLE 1 improvement of senile pruritus in different groups
As a result: the data show that the heart-soothing and lipid-lowering tablets, the pseudo-ginseng tablets and the pulse-invigorating tablets are externally applied to the affected part or orally taken, the inefficiency is highest, the effective rate is very low (all of which are not more than 60 percent), and the effect of treating senile cutaneous pruritus of the heart-soothing and lipid-lowering tablets, the pseudo-ginseng tablets and the pulse-invigorating tablets is poor. The oral preparation (example 2) has the lowest ineffective rate and the highest effective rate which is more than 90 percent, and has significant difference with heart-soothing and lipid-lowering tablets, pseudo-ginseng tablets and Yimaikang tablets, which shows that the oral preparation (example 2) has the effect on senile pruritus cutanea both by oral administration and external application.
And (4) testing: 100 people are summoned, the age is 40-70 years, and the half of men and women are divided into 4 groups, and an observation test for improving the migraine is carried out. Group A, SHUXINJIANGZHI tablet, is administered orally with warm water 3 times daily, 4 tablets each time. Group B oral formulations (example 2) were treated orally, directly, 3 times a day, 1 strip at a time. Group C Notoginseng tablet (prepared by pulverizing Notoginseng radix 500g into fine powder, adding adjuvant, granulating, and making into 1000 tablets) is taken with warm water 3 times a day and 6 tablets once. Group D Yimaikang tablet (prepared by mixing herba Erigerontis extract 160g with starch 150g, drying at below 75 deg.C, pulverizing, adding dextrin, granulating with 60% ethanol, making into 1000 tablets, and coating with sugar coating) for treatment, and is swallowed with warm water 3 times a day, 2 tablets once. Each group was treated for 2 weeks. The results are shown in Table 2 below.
TABLE 2 improvement of migraine in different groups
As a result: the data show that only the basic cure rate and the effective rate of the oral preparation (example 2) in the group B are the highest, the ineffective rate is the lowest, and the oral preparation has significant difference compared with other groups of data, so the oral preparation (example 2) in the group B has obvious effect of treating headache compared with the heart-soothing and lipid-lowering tablets, the pseudo-ginseng tablets and the pulse-invigorating and health-promoting tablets.
Finally, it is noted that the above-mentioned preferred embodiments illustrate rather than limit the invention, and that, while the invention has been described in detail with reference to the above-mentioned preferred embodiments, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the scope of the invention as defined by the appended claims.
Claims (6)
1. An oral preparation for relaxing heart and reducing blood fat, which is characterized in that: the heart-soothing lipid-lowering oral preparation comprises the following raw materials in parts by weight: 60-80 parts of salvia miltiorrhiza bunge, 10-18 parts of giant knotweed, 11000-15000 parts of pseudo-ginseng, 5-10 parts of dalbergia wood, 10000-14000 parts of kudzu root, 2-8 parts of peach kernel, 10-15 parts of red paeony root, 50-90 parts of hawthorn, 10-17 parts of safflower, 10-18 parts of suberect spatholobus stem and 10-18 parts of erigeron breviscapus.
2. An oral formulation for soothing the heart and lowering lipid as claimed in claim 1, wherein: the heart-soothing lipid-lowering oral preparation further comprises the following raw materials in parts by weight: 10-60 parts of rubber powder, 1.5-450 parts of sweetener and 0.3-0.6 part of preservative.
3. An oral formulation for soothing the heart and lowering lipid as claimed in claim 2, wherein: the gelatine powder is one or the combination of more of carrageenan, konjac glucomannan and gelatin.
4. An oral formulation for soothing the heart and lowering blood lipid as claimed in claim 2, wherein: the sweetener is one or the combination of any more of sucrose, xylitol, sucralose, glycyrrhizin and mogroside.
5. An oral formulation for soothing the heart and lowering blood lipid as claimed in claim 2, wherein: the preservative is one or the combination of any more of sorbic acid, potassium sorbate and sodium benzoate.
6. A process for the preparation of an oral formulation for soothing the heart and lowering the lipid levels as claimed in any one of claims 1 to 5, wherein: the method comprises the following steps: (1) Weighing the raw materials according to the parts by weight, decocting with water for 3 times, each time for 1.5 hours, filtering the decoction, combining the filtrates, and concentrating to obtain an extract with a relative density of 1.2 for later use;
(2) Weighing the rubber powder according to the weight parts, adding water to soak and dissolve, and obtaining a colloidal solution for later use after swelling or complete dissolution;
(3) Weighing a sweetening agent and a preservative according to parts by weight, adding water to dissolve, and heating to obtain syrup for later use;
(4) And (3) mixing the extractum, the colloidal solution and the syrup prepared in the steps (1), (2) and (3), adding water to reach the total weight of 1500 parts, uniformly mixing, filtering, sterilizing and subpackaging to obtain the traditional Chinese medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211103084.2A CN115381876A (en) | 2022-09-09 | 2022-09-09 | Oral preparation for relaxing heart and reducing fat and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211103084.2A CN115381876A (en) | 2022-09-09 | 2022-09-09 | Oral preparation for relaxing heart and reducing fat and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115381876A true CN115381876A (en) | 2022-11-25 |
Family
ID=84126159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211103084.2A Pending CN115381876A (en) | 2022-09-09 | 2022-09-09 | Oral preparation for relaxing heart and reducing fat and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115381876A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315188A (en) * | 2000-03-29 | 2001-10-03 | 云南文山华文企业集团三七产业高科技开发中心 | Buccal lozenge of superfine notoginseng powder |
| CN1733031A (en) * | 2005-08-30 | 2006-02-15 | 郭小波 | Brain caring oral liquid and its preparation process |
| CN104857154A (en) * | 2014-07-25 | 2015-08-26 | 苏庆文 | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor |
| CN105497794A (en) * | 2015-12-30 | 2016-04-20 | 平光制药股份有限公司 | Cholesterol-lowering and antithrombotic traditional Chinese medicine composition for warming channels and activating collaterals and preparation method of cholesterol-lowering and antithrombotic traditional Chinese medicine composition |
| CN108837036A (en) * | 2018-08-03 | 2018-11-20 | 威海康博尔生物药业有限公司 | A kind of blood fat-reducing blood pressure-decreasing, the preparation for preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof |
| CN114191515A (en) * | 2021-12-07 | 2022-03-18 | 云南植物药业有限公司 | Oral gel for dispelling dampness, invigorating stomach and improving immunity and preparation method thereof |
-
2022
- 2022-09-09 CN CN202211103084.2A patent/CN115381876A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315188A (en) * | 2000-03-29 | 2001-10-03 | 云南文山华文企业集团三七产业高科技开发中心 | Buccal lozenge of superfine notoginseng powder |
| CN1733031A (en) * | 2005-08-30 | 2006-02-15 | 郭小波 | Brain caring oral liquid and its preparation process |
| CN104857154A (en) * | 2014-07-25 | 2015-08-26 | 苏庆文 | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor |
| CN105497794A (en) * | 2015-12-30 | 2016-04-20 | 平光制药股份有限公司 | Cholesterol-lowering and antithrombotic traditional Chinese medicine composition for warming channels and activating collaterals and preparation method of cholesterol-lowering and antithrombotic traditional Chinese medicine composition |
| CN108837036A (en) * | 2018-08-03 | 2018-11-20 | 威海康博尔生物药业有限公司 | A kind of blood fat-reducing blood pressure-decreasing, the preparation for preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof |
| CN114191515A (en) * | 2021-12-07 | 2022-03-18 | 云南植物药业有限公司 | Oral gel for dispelling dampness, invigorating stomach and improving immunity and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100577023C (en) | Tea and drink with balanced nutrients | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN103893252A (en) | Composition capable of clearing heat from throat and relieving sore throat and preparation method and application thereof | |
| CN111264735A (en) | Functional beverage for strengthening body resistance, consolidating constitution, improving immunity, preventing and controlling epidemic toxin | |
| CN103169923B (en) | Traditional Chinese medicine composition for treating myocarditis and preparation method of traditional Chinese medicine composition | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN104383296A (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method of traditional Chinese medicine composition for treating xerophthalmia | |
| CN102716339A (en) | Chinese medicinal composition for treating uremia, and preparation method and application thereof | |
| CN105029421A (en) | Health care product for conditioning phlegm-dampness constitution | |
| CN107334870A (en) | A kind of composition of hypotensive and preparation method thereof | |
| CN107836620A (en) | A kind of health solid beverage and preparation method thereof | |
| CN102772777B (en) | Medicine for treating infantile pneumonia and preparation method thereof | |
| CN115381876A (en) | Oral preparation for relaxing heart and reducing fat and preparation method thereof | |
| CN111135235A (en) | A composition for preventing and relieving acute alcoholism or alcoholic intoxication | |
| CN108785559B (en) | Medicine for treating respiratory tract infection and preparation method thereof | |
| CN115399476A (en) | Food composition with auxiliary bowel relaxing function | |
| CN104840776A (en) | Traditional Chinese medicine for reducing blood pressure | |
| CN104800600A (en) | Medicine for treating hypertension | |
| CN103550351B (en) | Chinese medicine composition for the treatment of migraine and preparation method thereof | |
| CN108079271A (en) | A kind of pharmaceutical composition for treating hyperlipidemia, preparation and preparation method thereof | |
| CN107737250A (en) | A kind of hypertension Chinese medicine composition and preparation method thereof | |
| CN107007782A (en) | A kind of special effect Chinese composition for being used to treat toothache and canker sore | |
| CN1317003C (en) | Capsule comprising oriental cattail pollen and red sange root and technique for preparing the same | |
| CN113100367A (en) | Health-care beverage based on traditional Chinese medicine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221125 |